Clinical trial · Observational
18F-fluoroestradiol (18F-FES) PET/CT Guided First-line Treatment for HR+/HER2- Metastatic Breast Cancer Patients
A Single-center, Real-world Study Exploring the Guidance of FES-PET for First-line Treatment of HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer Patients
NCT06655545CI-TRIAL-00089394completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A single-center, real world study to evaluate the role of FES-PET in guiding the first-line treatment of HR+/HER2- MBC patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (4)
- label
- FES-guided CDK4/6 inhibitor plus endocrine therapy cohort
- description
- The group guided with FES-PET using a CDK4/6 inhibitor plus ET.
- label
- FES-guided chemotherapy cohort
- description
- The group guided with FES-PET using chemotherapy.
- label
- Non-FES-guided CDK4/6 inhibitor plus endocrine therapy cohort
- description
- The group examined without FES-PET using a CDK4/6 inhibitor plus ET.
- label
- Non-FES-guided chemotherapy cohort
- description
- The group examined without FES-PET using chemotherapy.
Primary outcomes (1)
- measure
- PFS
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. age \>= 18 years old; 2. Patients who were diagnosed as HR Positive, HER2 Negative recurrent unresectable (local or regional) or stage IV (M1) breast cancer between January 2020 to February 2024; 3. Received CDK4/6 inhibitor plus endocrine treatment or chemotherapy as first-line therapy for at least one cycle; 4. Complete medical history was available. Exclusion Criteria: 1\. Medical history was incomplete.
References
Publications (0)
Data not yet available
No reference posted for this study.